Which statement correctly ranks metabolic risk among the listed antipsychotics?

Which statement correctly ranks metabolic risk among the listed antipsychotics?

• A. Clozapine and Olanzapine have the highest risk
• B. Quetiapine and Risperidone have the highest risk
• C. Ziprasidone and Aripiprazole have no risk
• D. Lurasidone has the highest risk

Answer: (A)

Metabolic risk with antipsychotics is about how much they contribute to weight gain, dyslipidemia, and glucose intolerance. The pair with the highest metabolic risk is clozapine and olanzapine. They consistently cause substantial weight gain and worsen metabolic parameters like fasting glucose and lipid levels, increasing the likelihood of metabolic syndrome in many patients. This stronger effect is linked to receptor activity that promotes appetite and affects insulin sensitivity, notably strong histamine H1 and serotonin 5-HT2C blockade. Other antipsychotics tend to have lower metabolic impact. Quetiapine and risperidone can cause some weight gain and metabolic changes, but not to the extent seen with olanzapine or clozapine. Ziprasidone and aripiprazole are generally more weight neutral and have more favorable effects on lipids and glucose. Lurasidone also shows a favorable metabolic profile. So the statement identifying clozapine and olanzapine as having the highest metabolic risk best reflects the known differences in metabolic side effects among these agents.

Metabolic risk with antipsychotics is about how much they contribute to weight gain, dyslipidemia, and glucose intolerance. The pair with the highest metabolic risk is clozapine and olanzapine. They consistently cause substantial weight gain and worsen metabolic parameters like fasting glucose and lipid levels, increasing the likelihood of metabolic syndrome in many patients. This stronger effect is linked to receptor activity that promotes appetite and affects insulin sensitivity, notably strong histamine H1 and serotonin 5-HT2C blockade.

Other antipsychotics tend to have lower metabolic impact. Quetiapine and risperidone can cause some weight gain and metabolic changes, but not to the extent seen with olanzapine or clozapine. Ziprasidone and aripiprazole are generally more weight neutral and have more favorable effects on lipids and glucose. Lurasidone also shows a favorable metabolic profile. So the statement identifying clozapine and olanzapine as having the highest metabolic risk best reflects the known differences in metabolic side effects among these agents.